|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Hyperuricemia | |||||
| Leukemia | |||||
| Lymphoma | |||||
| 2 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Lymphatic Diseases | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Pathologic Processes | |||||
| 3 | Interventions listed in this trial | ||||
| Rasburicase (SR29142) | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Rasburicase | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antirheumatic Agents | |||||
| Gout Suppressants | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Sanofi-Aventis | |||||